RT Journal Article
SR Electronic
T1 The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00065-2022
DO 10.1183/23120541.00065-2022
A1 Katrien Eger
A1 Dora Paroczai
A1 Alison Bacon
A1 Florence Schleich
A1 Svetlana Sergejeva
A1 Arnaud Bourdin
A1 Isabelle Vachier
A1 Eleftherios Zervas
A1 Konstantinos Katsoulis
A1 Dimosthenis Papapetrou
A1 Konstantinos Kostikas
A1 Zsuzsanna Csoma
A1 Henrico Heffler
A1 Goergio Watler Canonica
A1 Ineta Grisle
A1 Kristina Bieksiene
A1 Jolita Palacionyte
A1 Anneke ten Brinke
A1 Simone Hashimoto
A1 Frank WJM Smeenk
A1 Gert-Jan Braunstahl
A1 Simone van der Sar
A1 Florin Mihălţan
A1 Natalia Nenasheva
A1 Marina Peredelskaya
A1 Biljana Zvezdin
A1 Ivan Čekerevac
A1 Sanja Hromiš
A1 Vojislav Ćupurdija
A1 Zorica Lazic
A1 Branislava Milenkovic
A1 Sanja Dimic-Janjic
A1 Valentyna Yasinska
A1 Barbro Dahlén
A1 Apostolos Bossios
A1 Nikolaos Lazarinis
A1 David Aronsson
A1 Arne Egesten
A1 Abul Kashem Mohammad Munir
A1 Lars Ahlbeck
A1 Christer Janson
A1 Sabina Škrgat
A1 Natalija Edelbaher
A1 Joerg Leuppi
A1 Fabienne Jaun
A1 Jochen Rüdiger
A1 Nikolay Pavlov
A1 Pietro Gianella
A1 Reta Fischer
A1 Florian Charbonnier
A1 Rekha Chaudhuri
A1 Steven James Smith
A1 Simon Doe
A1 Michelle Fawdon
A1 Matthew Masoli
A1 Liam Heaney
A1 Hans Michael Haitchi
A1 Ramesh Kurukulaaratchy
A1 Olivia Fulton
A1 Betty Frankemölle
A1 Toni Gibson
A1 Karen Needham
A1 Peter Howarth
A1 Ratko Djukanovic
A1 Elisabeth Bel
A1 Michael Hyland
YR 2022
UL http://openres.ersjournals.com/content/early/2022/03/10/23120541.00065-2022.abstract
AB Background The COVID-19 pandemic has put pressure on health-care services forcing the reorganisation of traditional care pathways. We investigated how physicians taking care of severe asthma patients in Europe reorganised care, and how these changes affected patient satisfaction, asthma control and future care.Methods In this European-wide cross-sectional study, patient surveys were sent to patients with a physician-diagnosis of severe asthma, and physician surveys to severe asthma specialists between November 2020 and May 2021.Results 1101 patients and 268 physicians from 16 European countries contributed to the study. Common physician-reported changes in severe asthma care included use of video/phone consultations (46%), reduced availability of physicians (43%) and change to home-administered biologics (38%). Change to phone/video consultations was reported in 45% of patients, of whom 79% were satisfied or very satisfied with this change. Of 709 patients on biologics, 24% experienced changes in biologic care, of whom 92% were changed to home-administered biologics and of these 62% were satisfied or very satisfied with this change. Only 2% reported worsening asthma symptoms associated with changes in biologic care. Many physicians expect continued implementation of video/phone consultations (41%) and home administration of biologics (52%).Conclusions Change to video/phone consultations and home administration of biologics was common in severe asthma care during the COVID-19 pandemic, and was associated with high satisfaction levels in most but not all cases. Many physicians expect these changes to continue in future severe asthma care, though satisfaction levels may change after the pandemic.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Jochen Rüdiger reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Education of swiss Emergency physicians. Participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim. Member of the Board of the Swiss Society of Pneumology and President Thorax section of the Swiss Ultrasound Society. All disclosures made outside the submitted work.Sabina Škrgat reports receiving honoraria for lectures and educational events, supported by GSK, Astra Zeneca, Sanofi, Chiesi, Pliva Teva and Medis. Participation on Advisory boards of GSK, Astra Zeneca, Chiesi and Sanofi. All disclosures made outside the submitted work.Simon Doe reports receiving support for attending meetings and/or travel from GSK and Sanofi, outside the submitted work.Simone van der Sar – van der Brugge reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca and GSK, Support received from ALK for attending meetings and/or travel. All disclosures made outside the submitted work.Dr Steven J Smith is Supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 831434 for Taxonomy, Targets, Treatment, and Remission. The JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associates. All disclosures made outside the submitted work.Zsuzsanna Csoma reports receiving honoraria for presentations: Astra/Zeneca, TEVA, Sanofi/Aventis (Hungary), outside the submitted work.Apostolos Bossios reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AZ, GSK, TEVA. Support for attending meetings and/or travel received from NOVARTIS. Participation on a Data Safety Monitoring Board or Advisory Board for AZ, GSK, NOVARTIS, TEVA, SANOFI. Member of the steering Committee of SHARP, Secretary of Assembly 5 (Airway diseases, asthma, COPD and chronic cough), European Respiratory Society; vice-chair of Nordic Severe Asthma Network (NSAN). All disclosures made outside the submitted work.Arnaud Bourdin reports receiving grants or contracts outside the submitted work from Astra Zeneca and Boeringher Ingelheim. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events as well as support for attending meetings and/or travel from Astra Zeneca, Boeringher Ingelheim, GSK, Novartis, Chiesi and Amgen, outside the submitted work.Arne Egesten reports receiving honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, outside the submitted work.David Aronsson reports receiving grants or contracts from ALK-Abello, outside the submitted work.Elisabeth H. Bel reports support for the present manuscript from ERS. Grants or contracts received from GlaxoSmithKline and Teva, outside the submitted work. Consulting fees received from AstraZeneca, GlaxoSmithKline, Sanofi, Sterna and Chiesi, outside the submitted work. Honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Teva. Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, outside the submitted work. Leadership or fiduciary role in other board, society, committee or advocacy group, unpaid for SHARP-CRC and RAPSODI (Dutch registry), outside the submitted work.Enrico Heffler reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca; Sanofi-Genzyme; Regeneron; Novartis; GSK; Circassia; Stallergenes-Greer; Nestlè Purina, outside the submitted work.Florian Charbonnier reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi, Novartis, Mundipharma, AstraZeneca, and GSK. Participation on a Data Safety Monitoring Board or Advisory Board for Sanofi, Novartis, Mundipharma, AstraZeneca, and GSK. All disclosures made outside the submitted work.Giorgio Walter CANONICA reports receiving consulting fees from AstraZeneca GSK, Novartis, Sanofi, and Stallergenes Greer. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, GSK, Novartis, Sanofi, Stallergenes Greer, Menarini, Chiesi, and Mylan. Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, GSK, Novartis, Sanofi, Stallergenes Greer, and Chiesi. All disclosures made outside the submitted work.Gert-Jan Braunstahl reports grants or contracts from GSK, AstraZeneca, and ALK Abello. Consulting fees from GSK, Sanofi, ALK Abello, AstraZeneca, and Novartis. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK, Sanofi, ALK Abello, AstraZeneca, and Novartis. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Scientific board Dutch Lung Foundation, Task force Asthma NVALT, editorial board NTVAAKI. All disclosures made outside the submitted work.Pietro Gianella reports participation on Advisory board Novartis about Xolair for Nasal polyps, outside the submitted work.Lars Ahlbeck reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca. Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Sanofi, and GSK. All disclosures made outside the submitted work.Liam Heaney reports grants or contracts from Medimmune, Novartis UK, Roche/Genentech Inc, and Glaxo Smith Kline, Amgen, Genentech / Hoffman la Roche, Astra Zeneca, Medimmune, Glaxo Smith Kline, Aerocrine and Vitalograph. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for Novartis, Hoffman la Roche/Genentech Inc, Sanofi, Glaxo Smith Kline, Astra Zeneca, Teva and Circassia. Support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals. Participation on a Data Safety Monitoring Board or Advisory Board for Novartis, Hoffman la Roche/Genentech Inc, Sanofi, Evelo Biosciences, Glaxo Smith Kline, AstraZeneca, Teva, Theravance, and Circassia. All disclosures made outside the submitted work.Matthew Masoli reports receiving grants or contracts from ERS SHARP to support the study ‘The burden of severe asthma on HRQoL across Europe’, outside the submitted work.Michael Hyland reports receiving grants or contracts from TEVA. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for GSK. All disclosures made outside the submitted work.Natalia Nenasheva reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca plc., Sanofi S.A., Teva Pharmaceuticals, Novartis International AG, and Chiesi Farmaceutici S.p.A., outside the submitted work.Natalija Edelbaher reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK, Astra Zeneca, Chiesi, Pliva Teva, Krka, Novartis, Boehringer Ingelheim, and Sanofi. The author reports participation on Advisory boards of GSK, Astra Zeneca, Chiesi, Novartis, and Boehringer Ingelheim. All disclosures made outside the submitted work.Nikolay Pavlov reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK, Novartis, and OM Pharma. Support for attending meetings and/or travel received from Boehringer Ingelheim. Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, GSK, Novartis, and Sanofi. All disclosures made outside the submitted work.Peter Howarth reports to be employed by GSK.Ratko Djukanovic reports support for the present manuscript received from ERS, TEVA, GSK, Novartis, Sanofi, and Chiesi. Consulting fees from Synairgen for which the author is a co-founder and consultant and owns shares, outside the submitted work. Participation on a Data Safety Monitoring Board or Advisory Board for Kymab (Cambridge), outside the submitted work.Rekha Chaudhuri reports receiving grants or contracts from AstraZeneca. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for GSK, AstraZeneca, Teva, Chiesi, Sanofi, and Novartis. Support for attending meetings and/or travel received from Chiesi, Napp, Sanofi, Boehringer, GSK, and AZ. Participation on a Data Safety Monitoring Board or Advisory Board for GSK, AstraZeneca, Teva, Chiesi, and Novartis. All disclosures made outside the submitted work.The remaining authors have nothing to disclose.